Hannes Snellman Advised Faron Pharmaceuticals Ltd in Its Convertible Bond Arrangement of up to EUR 35 million and the Issuance of Amortising Unsecured Convertible Bonds

Hannes Snellman advised Faron Pharmaceuticals Ltd in its convertible bond arrangement of up to EUR 35 million and the issuance of amortising unsecured convertible bonds in connection with the refinancing of the company’s existing senior secured loan. Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatment of cancers via novel immunotherapies. Faron’s shares are listed on Nasdaq First North Growth Market Finland and as depositary interests, representing entitlements to shares, on AIM in the United Kingdom.

Hannes Snellman’s core advisory team comprised Anniina Järvinen, Riikka Rannikko, Robert Gordin, and Claes Backström (Capital Markets and Corporate), Josefina Aalto (Finance), Jenni Parviainen (Tax), and Legal Assistant Anni Nohteri.